Fairchild Medical Center Critical Access Hospital (Medicare Certified) Location: 444 Bruce Street, Yreka, California 96097 Ratings: Phone: (530) 842-4121 |
News Archive
A chemically-modified version of a mitochondrial toxin long used to control species of invasive fish in lakes has been found to selectively inhibit two "survival proteins" in cancer cells.
Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients.
A new computational model has allowed researchers to identify new therapeutic targets that can attack cancer cells by lowering their intracellular pH. The study, which is the result of collaboration between IRB Barcelona, the Moffitt Cancer Center, and the University of Maryland, has been published in Nature Communications.
Medtronic, Inc. announced findings from an economic sub-study of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial published in the European Heart Journal demonstrating for the first time that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients.
Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.
› Verified 7 days ago